Patient and Treatment Characteristics for 106 Breast Cancer Patients Undergoing NAC

106 patients with stage I-III breast cancer receiving neoadjuvant chemotherapy (NAC) were monitored with ultrasound imaging at weeks 0, 1, 4, 8, 12, and 16. The dataset, authored by Erika Z. Chung and last updated in 2026, contains patient and treatment characteristics, with tumor size changes evaluated as predictors of final pathological response categorized as Complete, Partial, Weak, or Non-Responder.

Use Cases

• Predict final pathological response to NAC based on early changes in tumor diameter, area, and volume.
• Compare tumor size reduction trajectories between Complete Responders, Partial Responders, Weak Responders, and Non-Responders.
• Validate ultrasound imaging as an early predictive tool for chemotherapy efficacy in breast cancer.

Strengths

• Includes data from 106 patients, providing a specific cohort size.
• Contains longitudinal ultrasound measurements at six specific time points during treatment.
• Uses a defined four-category pathological response grading system (CR, PR, WR, NR).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The 9.5 KB file size indicates a very limited scope of data.

Provenance

Source

figshare

Collection Method

Clinical study of patients receiving standard neoadjuvant chemotherapy and undergoing scheduled ultrasound imaging.

Freshness

Last updated 2026-05-27 17:32:43; freshness should be verified.